2017 annual financial data
Spero Therapeutics 2017 Operating cash flow margin
Direct answer
Operating cash flow margin was -1,976.3%.
Operating income was -41,730,000 USD and net income was -46,097,000 USD.
Operating cash flow was -39,111,000 USD.
Get free Spero Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 1,979,000 USD
- Operating income
- -41,730,000 USD
- Net income
- -46,097,000 USD
- Operating cash flow
- -39,111,000 USD